BioCryst to Announce Third Quarter 2016 Financial Results November 7

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2016 financial results will be released on Monday, November 7, 2016.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company’s clinical development programs.  The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX7353 and other second generation compounds; and (galidesivir) formerly BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

CONTACT:     Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910